CAH:NYE-Cardinal Health, Inc (USD)

COMMON STOCK | Medical Distribution | NYE

Last Closing Price

USD 58.98

Change

-0.65 (-1.09)%

Market Cap

USD 17.30B

Volume

2.57M

Avg Analyst Target

USD 64.00 (+8.51%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. The company operates through two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. It also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and offers pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers. In addition, this segment repackages generic pharmaceuticals and over-the-counter healthcare products. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products. It also provides incontinence, nutritional delivery, wound care, cardiovascular, and endovascular products; single-use surgical drapes, gowns and apparel, and fluid suction and collection systems; urology products; operating room supplies; and electrode products. In addition, this segment distributes a range of national brand products, including medical, surgical, and laboratory products; and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-04 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MCK McKesson Corporation

-1.05 (-0.51%)

USD31.93B 13.93 8.79
ABC AmerisourceBergen Corporation

+1.84 (+1.49%)

USD25.66B 18.70 14.01
OMI Owens & Minor, Inc

-3.76 (-8.79%)

USD3.21B 25.44 11.76
PBH Prestige Consumer Healthcare I..

-0.24 (-0.45%)

USD2.67B 16.44 12.99
7459 Medipal Holdings Corp

N/A

N/A N/A N/A

ETFs Containing CAH

Symbol Name Weight Mer Price(Change) Market Cap
BFOR Barron's 400 ETF 0.00 % 0.70 %

-0.29 (-0.48%)

USD0.14B
DVP Roundhill Acquirers Deep .. 0.00 % 0.59 %

N/A

USD0.02B
ESGL Invesco ESG Revenue ETF 0.00 % 0.40 %

N/A

USD0.03B
RWL Invesco S&P 500 Revenue E.. 0.00 % 0.39 %

-0.76 (-1.01%)

USD1.08B
IVFVC Ivy Focused Value NextSha.. 0.00 % 0.78 %

N/A

USD8.39M
SUSB iShares ESG 1-5 Year USD .. 0.00 % 0.12 %

-0.02 (-0.08%)

USD1.05B
DXSP:XETRA Xtrackers - Euro Stoxx 50.. 0.00 % 0.40 %

-0.05 (-0.55%)

USD0.17B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Distribution)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.12% 20% F 51% F
Dividend Return 1.82% 100% A+ 53% F
Total Return 11.94% 20% F 51% F
Trailing 12 Months  
Capital Gain 2.40% 20% F 21% F
Dividend Return 3.38% 100% A+ 52% F
Total Return 5.78% 20% F 21% F
Trailing 5 Years  
Capital Gain -30.09% 20% F 15% F
Dividend Return 11.21% 100% A+ 40% F
Total Return -18.87% 20% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain -6.72% 20% F 9% F
Dividend Return 3.30% 100% A+ 71% C-
Total Return -3.42% 20% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 16.70% 80% B- 64% D
Risk Adjusted Return -20.46% 20% F 7% F
Market Capitalization 17.30B 60% D- 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Distribution)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 15.27 80% B- 58% F
Price/Book Ratio 9.63 20% F 11% F
Price / Cash Flow Ratio 8.83 80% B- 48% F
EV/EBITDA 10.07 80% B- 64% D
Management Effectiveness  
Return on Equity 76.93% 100% A+ 97% A+
Return on Invested Capital 16.17% 60% D- 88% B+
Return on Assets 2.77% 20% F 56% F
Debt to Equity Ratio 376.75% 20% F 8% F
Technical Ratios  
Short Ratio 1.80 80% B- 55% F
Short Percent 1.28% 80% B- 73% C
Beta 1.08 20% F 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector